The Role of Programmed Cell Death Receptor 1 in Lung Cancer

被引：3

作者：

Badiu, Dumitru Cristinel ^{[1
]}

Zgura, Anca ^{[2
]}

Mehedintu, Claudia ^{[3
]}

Haineala, Bogdan ^{[4
]}

Anghel, Rodica ^{[2
]}

Bacinschi, Xenia ^{[2
]}

机构：

[1] Carol Davila Univ Med & Pharm, Dept Gen Surg, Bagdasar Arseni Clin Emergency Hosp, Bucharest, Romania

[2] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Obstet Radiotherapy, Bucharest, Romania

[3] Carol Davila Univ Med & Pharm, Dept Obstet & Gynecol, Malaxa Clin Hosp, Bucharest, Romania

[4] Carol Davila Univ Med & Pharm, Dept Urol, Fundeni Clin Inst, Bucharest, Romania

来源：

IN VIVO | 2022年 / 36卷 / 02期

关键词：

Lung cancer; immune cells; lymphocytes; chemotherapy; programmed death 1; PD-L1; EXPRESSION; PROGNOSTIC-SIGNIFICANCE; ASSOCIATION;

D O I：

10.21873/invivo.12794

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer. The association between PD-L1 expression and clinicopathological characteristics in lung cancer is still unclear. Patients and Methods: This is a cross-sectional, observational study that evaluated a sample of 41 lung cancer patients diagnosed between March 2019 and December 2020. PD-L1 tumor expression is described as a percentage. Results: Patients were diagnosed with nonmicrocellular lung cancer and aged 37 to 87 years. Most patients were diagnosed with adenocarcinoma. According to the analysis, the average age of patients with negative PDL1 tumors was 65.6 years, and of those with positive PD-L1 tumors was 63.6 years. The average value of the tumor proportion score for males was 26.97%, and for females 25.55%. Conclusion: No correlation was found between PDL1 tumor expression and the age and sex of patients.

引用

页码：1007 / 1012

页数：6

共 20 条

[1]

Broaddus VC, 2016, Murray and Nadels' Textbook of Respiratory Medicine

[2] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients [J].

D'Incecco, A. ;

Andreozzi, M. ;

Ludovini, V. ;

Rossi, E. ;

Capodanno, A. ;

Landi, L. ;

Tibaldi, C. ;

Minuti, G. ;

Salvini, J. ;

Coppi, E. ;

Chella, A. ;

Fontanini, G. ;

Filice, M. E. ;

Tornillo, L. ;

Incensati, R. M. ;

Sani, S. ;

Crino, L. ;

Terracciano, L. ;

Cappuzzo, F. .

BRITISH JOURNAL OF CANCER, 2015, 112 (01) :95-102

[3] Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets [J].

Dalurzo, Mercedes L. ;

Aviles-Salas, Alejandro ;

Soares, Fernando Augusto ;

Hou, Yingyong ;

Li, Yuan ;

Stroganova, Anna ;

Oz, Buge ;

Abdillah, Arif ;

Wan, Hui ;

Choi, Yoon-La .

ONCOTARGETS AND THERAPY, 2021, 14 :4671-4692

[4] Immunotherapy in treatment naive advanced non-small cell lung cancer [J].

Ernani, Vinicius ;

Ganti, Apar Kishor .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S412-S421

[5] The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay [J].

Evans, Matthew ;

O'Sullivan, Brendan ;

Hughes, Frances ;

Mullis, Tina ;

Smith, Matthew ;

Trim, Nicola ;

Taniere, Philippe .

PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (01) :79-89

[6] Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].

Freeman, GJ ;

Long, AJ ;

Iwai, Y ;

Bourque, K ;

Chernova, T ;

Nishimura, H ;

Fitz, LJ ;

Malenkovich, N ;

Okazaki, T ;

Byrne, MC ;

Horton, HF ;

Fouser, L ;

Carter, L ;

Ling, V ;

Bowman, MR ;

Carreno, BM ;

Collins, M ;

Wood, CR ;

Honjo, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034

[7] The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups [J].

Jaklitsch, Michael T. ;

Jacobson, Francine L. ;

Austin, John H. M. ;

Field, John K. ;

Jett, James R. ;

Keshavjee, Shaf ;

MacMahon, Heber ;

Mulshine, James L. ;

Munden, Reginald F. ;

Salgia, Ravi ;

Strauss, Gary M. ;

Swanson, Scott J. ;

Travis, William D. ;

Sugarbaker, David J. .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 144 (01) :33-38

[8] The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients [J].

Li, Huijuan ;

Xu, Yangyang ;

Wan, Bing ;

Song, Yong ;

Zhan, Ping ;

Hu, Yangbo ;

Zhang, Qun ;

Zhang, Fang ;

Liu, Hongbing ;

Li, Tianhong ;

Sugimura, Haruhiko ;

Cappuzzo, Federico ;

Lin, Dang ;

Lv, Tangfeng .

TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (04) :429-+

[9] Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis [J].

Pan, Zhen-Kui ;

Ye, Feng ;

Wu, Xuan ;

An, Han-Xiang ;

Wu, Jing-Xun .

JOURNAL OF THORACIC DISEASE, 2015, 7 (03) :462-470

[10] Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers [J].

Pawelczyk, Konrad ;

Piotrowska, Aleksandra ;

Ciesielska, Urszula ;

Jablonska, Karolina ;

Glatzel-Plucinska, Natalia ;

Grzegrzolka, Jedrzej ;

Podhorska-Okolow, Marzenna ;

Dziegiel, Piotr ;

Nowinska, Katarzyna .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04)

← 1 2 →